[go: up one dir, main page]

BR0113661A - Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2 - Google Patents

Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2

Info

Publication number
BR0113661A
BR0113661A BR0113661-5A BR0113661A BR0113661A BR 0113661 A BR0113661 A BR 0113661A BR 0113661 A BR0113661 A BR 0113661A BR 0113661 A BR0113661 A BR 0113661A
Authority
BR
Brazil
Prior art keywords
cyclooxygenase
pharmaceutical compositions
enzyme inhibitors
topical release
topical
Prior art date
Application number
BR0113661-5A
Other languages
English (en)
Inventor
Vinod Kumar Arora
Ajay Kumar Singla
Mukesh Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0113661A publication Critical patent/BR0113661A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS PARA A LIBERAçãO TóPICA DE INIBIDORES DA ENZIMA CICLOOXIGENASE-2". A presente invenção refere-se a uma composição farmacêutica para liberação tópica compreendendo uma quantidade efetiva de uma droga que atua seletivamente como inibidora da enzima ciclooxigenase-2.
BR0113661-5A 2000-08-29 2001-08-28 Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2 BR0113661A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN779DE2000 IN191090B (pt) 2000-08-29 2000-08-29
PCT/IB2001/001557 WO2002017923A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors

Publications (1)

Publication Number Publication Date
BR0113661A true BR0113661A (pt) 2004-07-06

Family

ID=11097085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113661-5A BR0113661A (pt) 2000-08-29 2001-08-28 Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2

Country Status (13)

Country Link
US (1) US20040029946A1 (pt)
EP (1) EP1315500A4 (pt)
JP (1) JP2004525859A (pt)
CN (1) CN1227012C (pt)
AU (1) AU2001284321A1 (pt)
BR (1) BR0113661A (pt)
CA (1) CA2420804A1 (pt)
CZ (1) CZ2003822A3 (pt)
IN (1) IN191090B (pt)
RU (1) RU2003108335A (pt)
SK (1) SK3622003A3 (pt)
WO (1) WO2002017923A1 (pt)
ZA (1) ZA200301680B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
PL367337A1 (en) * 2001-05-31 2005-02-21 Pharmacia Corporation Skin-permeable selective cyclooxygenase-2 inhibitor composition
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
EP1534235B1 (en) 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
AU2003238543B2 (en) * 2002-06-25 2008-02-28 Acrux Dds Pty Ltd Transdermal aerosol compositions
JP4283507B2 (ja) * 2002-08-02 2009-06-24 久光製薬株式会社 経皮投与用貼付剤
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2005027939A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
WO2005037157A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
US20070196301A1 (en) 2005-12-21 2007-08-23 L'oreal Cosmetic composition with a volumizing effect
FR2894811B1 (fr) † 2005-12-21 2008-02-22 Oreal Composition cosmetique a effet volumateur
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
EP2658563B1 (en) 2010-12-28 2017-11-15 Mary Kay, Inc. Sebum control and anti-acne composition
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP6495723B2 (ja) * 2015-04-14 2019-04-03 帝國製薬株式会社 セレコキシブの経皮吸収製剤
CN105663032A (zh) * 2016-02-23 2016-06-15 青岛科技大学 一种维他昔布软膏剂的制备方法
SMT202200330T1 (it) 2016-08-02 2022-11-18 Univ Virginia Commonwealth Composizioni comprendenti 5-colesten-3, 25-diolo, 3-solfato (25hc3s) o suo sale farmaceuticamente accettabile e almeno un oligosaccaride ciclico
CN107158407A (zh) * 2017-06-17 2017-09-15 安徽仁之堂药业有限公司 一种中药提取所得挥发油的制剂助剂
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2075837B (en) * 1980-05-14 1984-03-14 Hisamitsu Pharmaceutical Co Topical pharmaceutical gel containing anti-inflammatory analgesic agents
US4602040A (en) * 1983-04-18 1986-07-22 Warner-Lambert Company Meclofenamic acid topical pharmaceutical composition
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
RU2200158C2 (ru) * 1995-02-13 2003-03-10 Джи.Ди.Сирл энд Ко. Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
GB2340751B (en) * 1998-08-12 2003-11-05 Edko Trading Representation Pharmaceutical compositions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AU5460800A (en) * 1999-06-02 2000-12-18 Aviana Biopharm Pharmaceutical transdermal compositions
IN191512B (pt) * 2000-01-21 2003-12-06 Panacea Biotech

Also Published As

Publication number Publication date
JP2004525859A (ja) 2004-08-26
US20040029946A1 (en) 2004-02-12
RU2003108335A (ru) 2004-09-10
CN1469748A (zh) 2004-01-21
CA2420804A1 (en) 2002-03-07
WO2002017923A1 (en) 2002-03-07
AU2001284321A1 (en) 2002-03-13
EP1315500A4 (en) 2006-05-31
ZA200301680B (en) 2004-06-23
CZ2003822A3 (cs) 2003-08-13
EP1315500A1 (en) 2003-06-04
IN191090B (pt) 2003-09-20
CN1227012C (zh) 2005-11-16
SK3622003A3 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
BR0113661A (pt) Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
BRPI0507972A (pt) composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
HN2001000146A (es) Derivados de pirazol
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
CR11106A (es) Inhibidores de cinasa p710 s6
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
DK1105114T3 (da) Nimesulidholdige topiske farmaceutiske sammensætninger
BR0312921A (pt) Composição compreendendo inibidor de reductase hmg-coa
HN2000000060A (es) Composiciones solidad que contienen gabapentina y proceso para su preparacion.
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente
PA8571901A1 (es) Nueva composicion farmaceutica
BRPI0408848A (pt) formulações orais de cladribine
ES2192263T3 (es) Derivados de benzo(c)quinolizina, su preparacion y empleo como inhibidores de 5-alfa-reductasas.
PA8547801A1 (es) Microcápsula para la protección frente al mal aliento
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
BR0013515A (pt) Inibidores de sintase de ácido graxo
AR023219A1 (es) Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A, 6A E 7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.